{
    "clinical_study": {
        "@rank": "73909", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1 : Droperidol 1,25 mg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Arm 2 : Droperidol 0,625 mg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Arm 3 : Odansetron 4 mg", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective of this study is to evaluate the incidence of akathisia with Droperidol,\n      the prophylactic treatment of post operative nausea and vomiting, used at two different\n      doses, versus control group (Ondansetron), in outpatient surgery.The primary endpoint is to\n      compare the number of observed akathisia (Barnes score > 1) in the Droperidol arms (0,625 mg\n      and 1,25 mg) versus Ondansetron 4 hours after recovery from anesthesia.The assumption is\n      that there is a greater risk of akathisia among patients taking Droperidol in prevention of\n      NPVO, that among patients taking Ondansetron."
        }, 
        "brief_title": "Akathisia in Post Operative Outpatients Surgery", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Akathisia", 
        "condition_browse": {
            "mesh_term": "Psychomotor Agitation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient over 18 and under 65 year-old\n\n          -  Having a moderate to severe POVN (post operative vomiting and nausea) risk, meaning\n             with at least two risk factors in the simplified Apfel score\n\n          -  Outpatient surgery associated to a general anesthesia\n\n          -  Patient having signed an informed consent- Patient having a social protection\n\n        Exclusion Criteria:\n\n          -  Contraindication to Droperidol\n\n          -  Contraindication to Ondansetron\n\n          -  Patients usually treated with benzodiazepine or having been treated with\n             benzodiazepine within 2 days prior to anesthesia\n\n          -  Psychiatric and Neurodegenerative diseases\n\n          -  Severe Anxiety\n\n          -  Contraindication to general anesthesia or one of its components\n\n          -  Allergy to propofol\n\n          -  Inability to get informed (patient in an emergency situation, difficulties to\n             understand)\n\n          -  Patient under judicial protection\n\n          -  Patient under tutorship or curatorship\n\n          -  Pregnancy reported by the patient- Breastfeeding\n\n          -  Patient in an exclusion period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942343", 
            "org_study_id": "5505"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm 1 : Droperidol 1,25 mg", 
                "Arm 2 : Droperidol 0,625 mg", 
                "Arm 3 : Odansetron 4 mg"
            ], 
            "intervention_name": "Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Droperidol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 12, 2013", 
        "location": {
            "contact": {
                "email": "antoine.charton@]chru-strasbourg.fr", 
                "last_name": "antoine Charton, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Strasbourg", 
                    "country": "France", 
                    "state": "Alsace", 
                    "zip": "67000"
                }, 
                "name": "Les H\u00f4pitaux Universitaires de Strasbourg"
            }, 
            "investigator": {
                "last_name": "Antoine Charton, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Etude de l'Effet du drop\u00e9ridol et de l'Ondansetron Sur l'Incidence de l'Akathisie Post op\u00e9ratoire en Chirurgie Ambulatoire", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The main objective of this study was to evaluate the incidence of akathisia with the waning of prophylactic treatment of PONV with droperidol used two different doses versus control group (ondansetron), ambulatory surgery", 
            "measure": "Incidence of akathisia", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942343"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Hospital, Strasbourg, France", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Strasbourg, France", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}